Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass

Journal of Cardiovascular Surgery

Volumn 50, Issue 5, 2009, Pages 687-694

  Tamayo, E ^a   Alvarez F J ^b   Alonso, O ^a   Bustamante, R ^c   Castrodeza, J ^b   Soria, S ^a   Lajo, C ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

^c UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Cardiopulmonary bypass; Cytokines; Heart, surgery; Hydroxymethylglutaryl CoA reductase inhibitors; Inflammation; Thoracic surgery

Indexed keywords

ALBUMIN; CREATINE KINASE; CREATINE KINASE MB; CREATININE; HEMOGLOBIN; INOTROPIC AGENT; INTERLEUKIN 6; INTERLEUKIN 8; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALBUMIN BLOOD LEVEL; AORTA CLAMPING; ARTICLE; BLOOD TRANSFUSION; BODY TEMPERATURE; BREATHING RATE; CARBON DIOXIDE TENSION; CARDIOPULMONARY BYPASS; CENTRAL VENOUS PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFECT; ELECTIVE SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTUBATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOXEMIA; INTENSIVE CARE UNIT; INTRAOPERATIVE PERIOD; LENGTH OF STAY; LEUKOCYTE COUNT; LUNG INSUFFICIENCY; MALE; MEAN ARTERIAL PRESSURE; MORBIDITY; OPERATION DURATION; OXYGEN TENSION; PERIOPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT; TREATMENT FAILURE;

AGED; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70949085048     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Westaby S. Organ dysfunaion after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extra-corporeal circuit. Intensive Care Med 1987;13:89-95.
2. Kubala L, Ciz M, Vondracek J, Nemec P, Studeník P, Cizová H, Lojek A. Perioperative and postoperative course of cytokines and the metabolic aaivity of neutrophils in human cardiac operations and heart transplantation. J Thorac Cardiovasc Surg 2002;124:122-9.
3. Hill GE, Whitten CW, Landers DF. The influence of cardiopulmonary bypass of cytokine and cell to cell communication. J Cardiothorac Vasc Anesth 1997;11:367-75.
4. Hennein HA, Ebba H, Rodriguez JL, Merrick SH, Keith FM, Bronstein MH et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunaion after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108:626-35.
5. Schmidt H, Hennen R, Keller A, Russ M, Müller-Werdan U, Werdan K et al. Association of statin therapy and increased survival in patients with multiple organ dysfunaion syndrome. Intensive Care Med 2006;32:248-51.
6. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22:524-34.
7. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effeas of statins. Arterioscler Thromb Vasc Biol 2003;23:729-36.
8. Halcox JPJ, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004:109:(21 Suppl 1):II42-48.
9. Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004;94:497-500.
10. Collard CD, Body SC, Shernan SK, Wang S, Mangano DT. Multicenter Study of Perioperative Ischemia (MCSPI) Research Group, Inc; Ischemia Research and Education Foundation (IREF) Investigators. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006;132:392-400.
11. Willerson JT Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(21suppl): II2-10.
12. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:8-16.
13. Jansen PG, te Velthuis H, Wildevuur WR, Huybregts MA, Bulder ER, van der Spoel HI et al. Cardiopulmonary bypass with modified fluid and heparin-coated circuits cardiopulmonary bypass with heparin-coated circuits. Br J Anaesth 1996;76:13-9.
14. Tobin MJ. Advances in mechanical ventilation. N Engl J Med 2001;344:986-96.
15. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:644-55.
16. Helle M, Boeije L, de Groot ER, de Vos A, Arden LA. Sensitive ELISA for interleukin 6: deteaion of IL-6 in biological fluids: synovial fluids and sera. J Imunnol Methods 1991;138:47-55.
17. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D et al. International Sepsis Definitions Conference. 2001 SCCM/ ESICM/ ACCP/ ATS/ SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29:530-8.
18. Birjiniuk V. Patient outcomes in the assessment of myocardial injury following cardiac surgery. Ann Thorac Surg 2001;72:Suppl 2:208-13.
19. Poldermans D, Bax JJ, Kertai MD, Krenning B, Westerhout CM, Schinkel AF et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003;107:848-51.
20. AUi IS, Buth KJ. Preoperative statin use and outcomes following cardiac surgery. Int J Cardiol 2005;103:12-8.
21. Liakopoulos OJ, Dörge H, Schmitto JD, Nagorsnik U, Grabedünkel J, Schoendube FA. Effects of preoperative statin therapy on cytokines after cardiac surgery. Thorac Cardiovasc Surg 2006;54:250-4.
22. Florens E, Salvi S, Peynet J, Elbim C, Mallat Z, Bel A et al. Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinical study. J Card Surg 2001;16:232-9.
23. Prondzinsky R, Knüpfer A, Loppnow H, Redling F, Lehmann DW, Stabenow I et al. Surgical trauma affeas the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;129:760-6.
24. Engel JM, Welters I, Rupp M, Langefeld T, Ruwoldt R, Menges T et al. Influence of colloid fluids on polymorphonuclear granulocyte funaion in vivo. Acta Anaesthesiol Scand 2001;45:385-9.
25. Jaeger K, Heine J, Ruschulte H, Jüttner B, Scheinichen D, Kuse ER et al. Effects of colloidal resuscitation fluids on the neutrophil respiratory burst. Transfusion 2001;41:64-8.
26. Vincent JL. Dear Sirs, I'm sorry to say that I don't like you. Crit Care Med 1997;25:372-4.
27. Talmor M, Hydo L, Barie PS. Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness. Arch Surg 1999;134:81-7.
28. Malone DL, Kuhls D, Napolitano LM, McCarter R, Scalea T. Back to basics: validation of the admission systemic inflammatory response syndrome score in predicting outcome in trauma. J Trauma 2001;51:458-63.